ArticleOncotarget2018

Anti-miR-17 therapy delays tumorigenesis in MYC-driven hepatocellular carcinoma (HCC).

Renumathy Dhanasekaran et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.